

Appendix

Appendix Table 1: Linear regression analysis of predictors of change in global quality of life and dysphagia scores.

	Univariate linear regression		Multiple linear regression	
	Standardised coefficient	P value	Standardised coefficient	P value
Change in global quality of life score				
Age (years)	-0.131	0.42	-	-
Male sex	-0.079	0.63	-	-
Ethnicity				
<i>New Zealand European</i>	-0.014	0.93	-	-
<i>Māori</i>	-0.107	0.51	-	-
<i>Other ethnicity</i>	0.124	0.45	-	-
ASA physical status classification grade	-0.320	0.04	-0.381	0.002
Body mass index (kg/m ²)	0.180	0.27	-	-
Coronary artery disease	-0.247	0.12	-0.311	0.04
Chronic obstructive respiratory disease	-0.153	0.35	-	-
Diabetes mellitus	-0.015	0.93	-	-
Hypertension	-0.143	0.38	-	-
Current smoker	-0.067	0.68	-	-
Previous gastroscopy prior to diagnosis	-0.084	0.61	-	-
Anti-reflux medication dose (mg)	-0.201	0.22	-	-
Adenocarcinoma versus squamous cell carcinoma histology type	0.128	0.44	-	-
Additional chemotherapy	0.048	0.77	-	-
Additional radiotherapy	-0.146	0.37	-	-
Middle versus lower third tumour location	0.005	0.24	-	-
Stricture length (cm)	-0.030	0.88	-	-
EndoMAXX versus Niti-S covered stent type	-0.052	0.75	-	-
Length of palliative care involvement (months)	-0.136	0.42	-	-

Appendix Table 1: Linear regression analysis of predictors of change in global quality of life and dysphagia scores (continued).

	Univariate linear regression		Multiple linear regression	
	Standardised coefficient	P value	Standardised coefficient	P value
Change in dysphagia score				
Age (years)	0.095	0.56	-	-
Male sex	0.120	0.46	-	-
Ethnicity				
<i>New Zealand European</i>	0.078	0.63	-	-
<i>Māori</i>	0.094	0.56	-	-
<i>Other ethnicity</i>	-0.188	0.25	-	-
ASA physical status classification grade	0.267	0.10	0.199	0.18
Body mass index (kg/m ²)	-0.140	0.39	-	-
Coronary artery disease	0.039	0.81	-	-
Chronic obstructive respiratory disease	-0.140	0.39	-	-
Diabetes mellitus	0.057	0.73	-	-
Hypertension	0.174	0.28	-	-
Current smoker	-0.032	0.85	-	-
Previous gastroscopy prior to diagnosis	-0.027	0.87	-	-
Anti-reflux medication dose (mg)	-0.125	0.44	-	-
Adenocarcinoma versus squamous cell carcinoma histology type	-0.234	0.16	-	-
Additional chemotherapy	-0.429	0.006	-0.368	0.02
Additional radiotherapy	0.125	0.44	-	-
Middle versus lower third tumour location	0.251	0.14	0.121	0.43
Stricture length (cm)	0.236	0.15	-	-
EndoMAXX versus Niti-S covered stent type	0.109	0.52	-	-
Length of palliative care involvement (months)	-0.0234	0.89	-	-